<p>摩根大通（NYSE:JNJ - 获取免费报告）在周五发布的研究报告中，将其对强生公司的目标价格从 212.00 美元上调至 230.00 美元，MarketScreener 报道。该公司目前对该股票的评级为 “增持”。摩根大通的目标价格暗示该股票当前价格有 8.67% 的上涨潜力。</p>
<ul>
<li>5 个医疗保健股票值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>其他几家研究公司也最近发布了关于 JNJ 的报告。Argus 在 10 月 15 日的研究报告中将强生公司的目标价格设定为 210.00 美元。大和美国在 10 月 20 日的研究报告中将强生公司的评级从 “持有” 上调至 “强力买入”。桑福德·C·伯恩斯坦在 10 月 6 日的研究报告中将强生公司的目标价格从 172.00 美元上调至 193.00 美元，并给予该公司 “市场表现” 的评级。雷蒙德·詹姆斯金融在 10 月 15 日的报告中将强生公司的目标价格从 174.00 美元上调至 209.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，Cowen 在 10 月 14 日的研究报告中重申了对强生公司的 “买入” 评级。四位分析师对该股票给予了强力买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 207.55 美元。</p>
<p>获取 <strong>强生公司</strong> 的提醒：</p>
<p><strong>查看我们关于强生公司的最新报告</strong></p>
<h2>强生公司股价上涨 0.8%</h2>
<ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
<p>周五中午交易时，JNJ 股票上涨 1.64 美元，达到 211.65 美元。该公司的股票交易量为 6,919,148 股，而其平均交易量为 9,422,986 股。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。强生公司的 12 个月低点为 140.68 美元，12 个月高点为 212.27 美元。该公司的市值为 5099.3 亿美元，市盈率为 20.43，市盈增长比率为 2.34，贝塔值为 0.36。该公司的 50 日简单移动平均线为 196.09 美元，200 日简单移动平均线为 177.08 美元。</p>
<p>强生公司（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日发布了季度财报。该公司报告本季度每股收益为 2.26 美元。该业务本季度的收入为 240.2 亿美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。平均而言，研究分析师预测强生公司在当前财政年度将发布 10.58 美元的每股收益。</p>
<h2>强生公司的机构交易</h2>
<ul>
<li>3 只适合不安市场的防御性股票</li>
</ul>
<p>机构投资者最近对该股票的持仓进行了调整。Brighton Jones LLC 在第四季度将其在强生公司的持仓增加了 13.9%。Brighton Jones LLC 现在拥有 51,876 股该公司的股票，价值 7,502,000 美元，在此期间又购买了 6,332 股。United Bank 在第一季度将其在强生公司的持仓增加了 110.7%。United Bank 现在拥有 9,279 股该公司的股票，价值 1,539,000 美元，在上个季度又购买了 4,876 股。Cookson Peirce &amp; Co. Inc.在第一季度获得了强生公司的新股份，价值 208,000 美元。EverSource Wealth Advisors LLC 在第一季度将其在强生公司的持仓增加了 10.5%。EverSource Wealth Advisors LLC 现在拥有 19,646 股该公司的股票，价值 3,258,000 美元，在上个季度又购买了 1,863 股。最后，Forvis Mazars Wealth Advisors LLC 在第一季度将其在强生公司的股份增加了 37.6%。Forvis Mazars Wealth Advisors LLC 现在拥有 58,656 股该公司的股票，价值 9,728,000 美元。目前 69.55% 的股票由机构投资者和对冲基金持有。</p>
<h2>强生公司简介</h2>
<p>（获取免费报告）</p>
<p>强生公司是一家控股公司，专注于医疗领域产品的研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>什么是热门股票？热门股票的解释</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>MarketBeat 周回顾 – 12/8 - 12/12</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生公司吗？</h2>
<p>在你考虑强生公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而强生公司并不在名单上。</p>
<p>虽然强生公司目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>富国银行将强生（NYSE:JNJ）的目标价格从 212.00 美元上调至 230.00 美元，给予该股票 “增持” 评级。这表明相较于当前价格有 8.67% 的潜在上涨空间。最近，其他几家公司也更新了对 JNJ 的评级和目标价格。该股票的共识评级为 “适度买入”，共识目标价格为 207.55 美元</p>

<p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) had its price objective boosted by Wells Fargo &amp; Company from $212.00 to $230.00 in a research note issued on Friday,MarketScreener reports. The firm presently has an &#34;overweight&#34; rating on the stock. Wells Fargo &amp; Company's price objective suggests a potential upside of 8.67% from the stock's current price.</p>
<div class="lb-trans"><p>摩根大通（NYSE:JNJ - 获取免费报告）在周五发布的研究报告中，将其对强生公司的目标价格从 212.00 美元上调至 230.00 美元，MarketScreener 报道。该公司目前对该股票的评级为 “增持”。摩根大通的目标价格暗示该股票当前价格有 8.67% 的上涨潜力。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健股票值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Several other research firms have also recently issued reports on JNJ. Argus set a $210.00 price target on Johnson &amp; Johnson in a research note on Wednesday, October 15th. Daiwa America raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, October 20th. Sanford C. Bernstein raised their price objective on shares of Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a research note on Monday, October 6th. Raymond James Financial boosted their target price on Johnson &amp; Johnson from $174.00 to $209.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 15th. Finally, Cowen reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $207.55.</p>
<div class="lb-trans"><p>其他几家研究公司也最近发布了关于 JNJ 的报告。Argus 在 10 月 15 日的研究报告中将强生公司的目标价格设定为 210.00 美元。大和美国在 10 月 20 日的研究报告中将强生公司的评级从 “持有” 上调至 “强力买入”。桑福德·C·伯恩斯坦在 10 月 6 日的研究报告中将强生公司的目标价格从 172.00 美元上调至 193.00 美元，并给予该公司 “市场表现” 的评级。雷蒙德·詹姆斯金融在 10 月 15 日的报告中将强生公司的目标价格从 174.00 美元上调至 209.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，Cowen 在 10 月 14 日的研究报告中重申了对强生公司的 “买入” 评级。四位分析师对该股票给予了强力买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 207.55 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生公司</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>查看我们关于强生公司的最新报告</strong></p>
</div><h2>Johnson &amp; Johnson Trading Up 0.8%</h2>
<div class="lb-trans"><h2>强生公司股价上涨 0.8%</h2>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
</div><p>Shares of JNJ stock traded up $1.64 during mid-day trading on Friday, reaching $211.65. The company's stock had a trading volume of 6,919,148 shares, compared to its average volume of 9,422,986. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $212.27. The firm has a market capitalization of $509.93 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. The company's 50 day simple moving average is $196.09 and its 200-day simple moving average is $177.08.</p>
<div class="lb-trans"><p>周五中午交易时，JNJ 股票上涨 1.64 美元，达到 211.65 美元。该公司的股票交易量为 6,919,148 股，而其平均交易量为 9,422,986 股。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。强生公司的 12 个月低点为 140.68 美元，12 个月高点为 212.27 美元。该公司的市值为 5099.3 亿美元，市盈率为 20.43，市盈增长比率为 2.34，贝塔值为 0.36。该公司的 50 日简单移动平均线为 196.09 美元，200 日简单移动平均线为 177.08 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts predict that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生公司（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日发布了季度财报。该公司报告本季度每股收益为 2.26 美元。该业务本季度的收入为 240.2 亿美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。平均而言，研究分析师预测强生公司在当前财政年度将发布 10.58 美元的每股收益。</p>
</div><h2>Institutional Trading of Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生公司的机构交易</h2>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合不安市场的防御性股票</li>
</ul>
</div><p>Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC increased its position in Johnson &amp; Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its position in Johnson &amp; Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after buying an additional 4,876 shares in the last quarter. Cookson Peirce &amp; Co. Inc. acquired a new stake in shares of Johnson &amp; Johnson in the first quarter valued at $208,000. EverSource Wealth Advisors LLC lifted its position in shares of Johnson &amp; Johnson by 10.5% during the first quarter. EverSource Wealth Advisors LLC now owns 19,646 shares of the company's stock worth $3,258,000 after purchasing an additional 1,863 shares in the last quarter. Finally, Forvis Mazars Wealth Advisors LLC increased its stake in shares of Johnson &amp; Johnson by 37.6% in the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company's stock valued at $9,728,000 after buying an additional 16,019 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Brighton Jones LLC 在第四季度将其在强生公司的持仓增加了 13.9%。Brighton Jones LLC 现在拥有 51,876 股该公司的股票，价值 7,502,000 美元，在此期间又购买了 6,332 股。United Bank 在第一季度将其在强生公司的持仓增加了 110.7%。United Bank 现在拥有 9,279 股该公司的股票，价值 1,539,000 美元，在上个季度又购买了 4,876 股。Cookson Peirce &amp; Co. Inc.在第一季度获得了强生公司的新股份，价值 208,000 美元。EverSource Wealth Advisors LLC 在第一季度将其在强生公司的持仓增加了 10.5%。EverSource Wealth Advisors LLC 现在拥有 19,646 股该公司的股票，价值 3,258,000 美元，在上个季度又购买了 1,863 股。最后，Forvis Mazars Wealth Advisors LLC 在第一季度将其在强生公司的股份增加了 37.6%。Forvis Mazars Wealth Advisors LLC 现在拥有 58,656 股该公司的股票，价值 9,728,000 美元。目前 69.55% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生公司是一家控股公司，专注于医疗领域产品的研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>MarketBeat Week in Review – 12/8 - 12/12</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>什么是热门股票？热门股票的解释</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>MarketBeat 周回顾 – 12/8 - 12/12</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生公司吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑强生公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而强生公司并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生公司目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

强生（NYSE:JNJ）在富国银行公司被设定了新的 230.00 美元目标价